Tag: Novartis
-

Novartis Licenses Abogen’s ABO2203 in $7.8B mRNA Deal
Novartis will pay Abogen $575 million upfront for worldwide rights to ABO2203, an mRNA-encoded CD19×CD3 T-cell engager, while securing options on additional RNA programs in a deal potentially worth approximately $7.8 billion.
-

Novartis’ Pelacarsen Fails Phase 3 Lp(a)HORIZON Despite Lowering Lp(a)
Novartis and Ionis reported that pelacarsen lowered Lp(a) but failed to significantly reduce 4-point MACE in the Phase 3 Lp(a)HORIZON trial, raising new questions about the clinical validity of Lp(a) lowering.
-

Novartis Remibrutinib Delivers Two Phase 3 Wins in Relapsing Multiple Sclerosis
Novartis reported positive Phase 3 results for remibrutinib in both REMODEL-1 and REMODEL-2, with significant reductions in annualized relapse rate versus teriflunomide and no liver safety signal reported across the two studies.
